Novartis and Cognizant have expanded their partnership with a five-year agreement for integrated, AI-driven IT operations. The goal is to bring applications, infrastructure, and security together into a single end-to-end model, supported by automation and AI.
Novartis and Cognizant have been working together for over twenty years. With the new agreement, they aim to further optimize their IT operations. Cognizant will support Novartis with predictive IT management, autonomous self-service, and AI-driven software development.
Cognizant is utilizing its AI Builder approach and the Neuro AI platform for this purpose. This should lead to a scalable technology ecosystem that further enhances the deployment of AI within Novartis.
Integration of IT services
The new partnership focuses on the integration of fragmented IT services. By bringing together applications, infrastructure, security, digital workplaces, and platform services, efficiency should increase and complexity decrease. This should also improve the user experience and better align IT performance with Novartis’s business operations.
Additionally, the new model must support the further deployment of AI within Novartis. This is particularly important in the pharmaceutical sector, where reliability, regulatory compliance, and advanced data analytics are crucial.
AI at Scale
“The pharmaceutical sector is digitizing rapidly,” said Manoj Mehta, President of EMEA at Cognizant. “That places high demands on reliability, regulatory compliance, advanced data analytics, and the integration of AI on scalable platforms.”
With the expansion of the partnership, Cognizant aims to help Novartis deploy AI across the entire value chain. The company possesses deep expertise in sectors, processes, and engineering, making it possible to translate an organization’s unique context into technological systems.
The new agreement should help Novartis make its IT operations future-proof. By deploying AI and automation, the company can better respond to the rapidly changing demands in the pharmaceutical sector.